{"disease":{"id":"crohn-amp-39-s-disease-cd","name":"crohn amp 39 s disease cd"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07123350","title":"Evaluating the Shift From Intravenous to Subcutaneous Vedolizumab for Inflammatory Bowel Disease","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":120,"lead_sponsor_name":"Vanderbilt University Medical Center","has_results":false},{"nct_id":"NCT07010926","title":"A Double-Blind, Randomized, Placebo-Controlled Phase II Clinical Trial to Evaluate the Safety and Efficacy of L2-01 in Subjects With Crohn's Disease","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":120,"lead_sponsor_name":"L2 Bio, LLC","has_results":false}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}